Novavax (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Novavax" in English language version.

refsWebsite

Global rank English rank

20web.archive.org

1^st place

6reuters.com

49^th place

47^th place

6novavax.com

low place

4yahoo.com

38^th place

40^th place

3bizjournals.com

407^th place

241^st place

3fda.gov

447^th place

338^th place

2bloomberg.com

99^th place

77^th place

2fiercepharma.com

low place

8,921^st place

2fiercebiotech.com

low place

8,828^th place

2nasdaq.com

2,740^th place

2,050^th place

2nytimes.com

7^th place

2worldcat.org

5^th place

2forbes.com

54^th place

48^th place

2nih.gov

4^th place

1biocentury.com

low place

1europa.eu

68^th place

117^th place

1canada.ca

1,712^th place

1,063^rd place

1biopharmadive.com

low place

1asm.org

3,555^th place

low place

1investorplace.com

low place

1twitter.com

23^rd place

32^nd place

1cnbc.com

220^th place

155^th place

1fancycomma.com

low place

1bbc.co.uk

8^th place

10^th place

1theguardian.com

12^th place

11^th place

1cnn.com

28^th place

26^th place

1livemint.com

390^th place

227^th place

1cepi.net

low place

1japantimes.co.jp

389^th place

273^rd place

1tga.gov.au

3,984^th place

2,622^nd place

1washingtonpost.com

34^th place

27^th place

1prnewswire.com

406^th place

258^th place

1ox.ac.uk

613^th place

456^th place

1contagionlive.com

low place

1doi.org

2^nd place

1khn.org

low place

asm.org

"A Universal Influenza Vaccine: How Close Are We?". ASM.org. Retrieved 18 June 2021.

bbc.co.uk

"Covid-19: Novavax vaccine shows 89% efficacy in UK trials". BBC News. 29 January 2021. Retrieved 1 February 2021.

biocentury.com

Guy, Richard; Ohri, Gunjan. "Draghia-Akli, a veteran of J&J and Merck, joins Novavax as head of R&D". BioCentury. Retrieved 20 November 2024.

biopharmadive.com

Bell, Jacob (14 November 2016). "Novavax aims to rebound with restructuring, more trials". BioPharma Dive. Washington, D.C.: Industry Dive. Archived from the original on 29 March 2017. Retrieved 28 March 2017.

bizjournals.com

Gilgore, Sara (24 March 2020). "Novavax's seasonal flu vaccine just got great news. And it's a big deal". www.bizjournals.com. Retrieved 18 June 2021.
"Gaithersburg Biotech Receives Grant Worth up to $89 million". Bizjournals.com. Archived from the original on 1 April 2017. Retrieved 28 March 2017.
Gilgore, Sara (26 February 2020). "Novavax is working to advance a potential coronavirus vaccine. So are competitors". Washington Business Journal. Archived from the original on 16 March 2020. Retrieved 6 March 2020.

bloomberg.com

"Company Overview of Novavax, Inc". Bloomberg.com. Archived from the original on 24 February 2017. Retrieved 2 June 2019.
"Novavax Inc - Company Profile and News - Bloomberg Markets". Bloomberg.com.

canada.ca

"Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine". Health Canada, Government of Canada. 17 February 2022. Retrieved 21 February 2022.

cepi.net

"Our portfolio". Coalition for Epidemic Preparedness Innovations. Archived from the original on 21 October 2022. Retrieved 18 July 2023.

cnbc.com

"Novavax soars after U.S. government awards firm $1.6 billion for coronavirus vaccine development". cnbc.com. 7 July 2020.

cnn.com

edition.cnn.com

Howard, Jacqueline (14 June 2021). "Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial". CNN. Retrieved 14 June 2021.

contagionlive.com

Hoffman, Matt (25 April 2025). "FDA Requests Additional Trial of Novavax NVX-CoV2601 Vaccine Prior to Approval". ContagionLive. Retrieved 14 May 2025.

doi.org

Magnusson, Sofia E.; Altenburg, Arwen F.; Bengtsson, Karin Lövgren; Bosman, Fons; De Vries, Rory D.; Rimmelzwaan, Guus F.; Stertman, Linda (2018). "Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice". Immunologic Research. 66 (2): 224–233. doi:10.1007/s12026-018-8991-x. PMC 5899102. PMID 29594879.

europa.eu

ema.europa.eu

"EMA recommends Nuvaxovid for authorisation in the EU". European Medicines Agency (Press release). 20 December 2021. Retrieved 6 January 2022.

fancycomma.com

Nidhi Parekh (24 July 2020). "Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19". Archived from the original on 22 November 2020. Retrieved 24 July 2020.

fda.gov

"Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted". Food and Drug Administration. 13 July 2022.^{[dead link]}
Research, Center for Biologics Evaluation and (2 October 2023). "Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) Authorized For Individuals 12 Years of Age and Older". FDA. Archived from the original on 5 May 2023.
"May 16, 2025 Approval Letter - NUVAXOVID". FDA. 16 May 2025. Archived from the original on 17 May 2025. Retrieved 18 May 2025.

fiercebiotech.com

Adams, Ben (16 September 2016). "Novavax craters after Phase III RSV F vaccine failure; seeks path forward". FierceBiotech. Questex. Archived from the original on 18 August 2020. Retrieved 25 January 2020.
"With promising RSV data in hand, Novavax wins $89M Gates grant for PhIII | FierceBiotech". Fiercebiotech.com. Archived from the original on 14 April 2017. Retrieved 28 March 2017.

fiercepharma.com

Taylor, Nick Paul (3 June 2013). "Novavax makes $30M bid for adjuvant business". FiercePharma. Archived from the original on 14 September 2016. Retrieved 9 September 2016.
Sagonowsky, Eric (11 May 2020). "Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work". FiercePharma. Archived from the original on 16 May 2020. Retrieved 12 May 2020.

forbes.com

Herper, Matthew. "Gates Foundation Backs New Shot To Prevent Babies From Dying Of Pneumonia". Forbes. Archived from the original on 21 September 2016. Retrieved 28 March 2017.
"Novavax Covid Vaccine Provides Antibody Response Against Omicron, Data Suggests". forbes.com.

investorplace.com

"Novavax Secured a Critical Second-Place Finish". InvestorPlace. 10 November 2020. Retrieved 18 June 2021.

japantimes.co.jp

"Japan secures 150 million Novavax vaccine doses". The Japan Times. 7 September 2021. Retrieved 7 September 2021.

khn.org

Sarah Jane Tribble and Rachana Pradhan. Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed Kaiser Health News, Kaiser Family Foundation, 19 July 2021.

livemint.com

Leo, Leroy (27 March 2021). "Hope to launch Covovax by September, says Serum Institute CEO". mint. Retrieved 17 July 2021.

nasdaq.com

Shtrubel, Marty (12 December 2019). "3 Biotech Stocks That Offer the Highest Upside on Wall Street". Biotech. Nasdaq. Archived from the original on 26 January 2020. Retrieved 25 January 2020.
Budwell, George (20 January 2020). "3 Top Biotech Picks for 2020". Markets. Nasdaq. Novavax: A catalyst awaits. Archived from the original on 25 January 2020. Retrieved 25 January 2020.

nih.gov

ncbi.nlm.nih.gov

Magnusson, Sofia E.; Altenburg, Arwen F.; Bengtsson, Karin Lövgren; Bosman, Fons; De Vries, Rory D.; Rimmelzwaan, Guus F.; Stertman, Linda (2018). "Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice". Immunologic Research. 66 (2): 224–233. doi:10.1007/s12026-018-8991-x. PMC 5899102. PMID 29594879.

pubmed.ncbi.nlm.nih.gov

Magnusson, Sofia E.; Altenburg, Arwen F.; Bengtsson, Karin Lövgren; Bosman, Fons; De Vries, Rory D.; Rimmelzwaan, Guus F.; Stertman, Linda (2018). "Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice". Immunologic Research. 66 (2): 224–233. doi:10.1007/s12026-018-8991-x. PMC 5899102. PMID 29594879.

novavax.com

ir.novavax.com

"Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights - Feb 28, 2024". ir.novavax.com. Retrieved 1 May 2024.
"Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies". Novavax Inc. (Press release).
"Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine - Jan 31, 2022".
"Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate". Novavax Inc. (Press release). Archived from the original on 13 June 2021. Retrieved 19 June 2021.

novavax.com

Novavax Inc. 2020 Annual Report Archived 14 August 2021 at the Wayback Machine. Accessed 10 May 2021.
"Novavax addresses urgent global public health needs with innovative technology". novavax.com. Archived from the original on 10 September 2020. Retrieved 30 August 2020.

nytimes.com

Thomas, Katie; Twohey, Megan (16 July 2020). "How a Struggling Company Won $1.6 Billion to Make a Coronavirus Vaccine". The New York Times. ISSN 0362-4331. Retrieved 29 January 2021.
Zimmer, Carl (1 November 2021). "The Novavax vaccine, backed by Operation Warp Speed, has won its first authorization — in Indonesia". The New York Times. ISSN 0362-4331. Retrieved 15 December 2021.

ox.ac.uk

"Highly effective, R21/Matrix-M malaria vaccine developed by University of Oxford and the Serum Institute of India awarded WHO 'stamp of approval'". University of Oxford (Press release). 21 December 2023. Retrieved 28 December 2023.

prnewswire.com

Novavax, Inc. "Novavax's Nuvaxovid Receives Full Marketing Authorization in the EU for the Prevention of COVID" (Press release).

reuters.com

"Novavax's Ebola vaccine shows promise in early-stage trial". Reuters. 21 July 2017. Archived from the original on 2 October 2016. Retrieved 28 March 2017.
"Novavax RSV vaccine found safe for pregnant women, fetus". Reuters. 29 September 2016. Archived from the original on 7 October 2016. Retrieved 28 March 2017.
Rajan, Gnaneshwar; Fick, Maggie (4 December 2024). "Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million". Reuters. Retrieved 27 March 2025.
"Moderna, Novavax to produce more COVID-19 vaccines in S.Korea". Reuters. 22 May 2021. Retrieved 17 July 2021.
"Japan to purchase 150 mln doses of Takeda-produced Novavax vaccines - drugmaker". Reuters. 7 September 2021. Retrieved 7 September 2021.
O'Donnell, Carl (22 December 2021). "Novavax says COVID vaccine triggers immune response to Omicron variant". reuters.com.

tga.gov.au

"TGA provisionally approves Novavax (Biocelect Pty LTD's) COVID-19 vaccine NUVAXOVID". 20 January 2022.^{[permanent dead link]}

theguardian.com

Marsh, Sarah (21 May 2021). "Novavax volunteers in UK threaten to quit over approval delays. Participants cannot prove they are fully vaccinated on NHS app leaving them unable to travel to Europe". The Guardian.

twitter.com

"Since the very beginning, I have said that our state would lead the way to develop treatments and perhaps even a vaccine for #COVID19. This morning in Gaithersburg, I joined representatives of @Novavax and @IAmBioTech to provide an update on these efforts". Twitter.

washingtonpost.com

Carolyn Y. Johnson and Laurie McGinley. FDA advisers recommend authorizing Novavax coronavirus vaccine. Washington Post, 7 June 2022.

web.archive.org

"Company Overview of Novavax, Inc". Bloomberg.com. Archived from the original on 24 February 2017. Retrieved 2 June 2019.
Novavax Inc. 2020 Annual Report Archived 14 August 2021 at the Wayback Machine. Accessed 10 May 2021.
Taylor, Nick Paul (3 June 2013). "Novavax makes $30M bid for adjuvant business". FiercePharma. Archived from the original on 14 September 2016. Retrieved 9 September 2016.
"Novavax's Ebola vaccine shows promise in early-stage trial". Reuters. 21 July 2017. Archived from the original on 2 October 2016. Retrieved 28 March 2017.
Adams, Ben (16 September 2016). "Novavax craters after Phase III RSV F vaccine failure; seeks path forward". FierceBiotech. Questex. Archived from the original on 18 August 2020. Retrieved 25 January 2020.
"Novavax addresses urgent global public health needs with innovative technology". novavax.com. Archived from the original on 10 September 2020. Retrieved 30 August 2020.
Bell, Jacob (14 November 2016). "Novavax aims to rebound with restructuring, more trials". BioPharma Dive. Washington, D.C.: Industry Dive. Archived from the original on 29 March 2017. Retrieved 28 March 2017.
Shtrubel, Marty (12 December 2019). "3 Biotech Stocks That Offer the Highest Upside on Wall Street". Biotech. Nasdaq. Archived from the original on 26 January 2020. Retrieved 25 January 2020.
Budwell, George (20 January 2020). "3 Top Biotech Picks for 2020". Markets. Nasdaq. Novavax: A catalyst awaits. Archived from the original on 25 January 2020. Retrieved 25 January 2020.
"Gaithersburg Biotech Receives Grant Worth up to $89 million". Bizjournals.com. Archived from the original on 1 April 2017. Retrieved 28 March 2017.
"With promising RSV data in hand, Novavax wins $89M Gates grant for PhIII | FierceBiotech". Fiercebiotech.com. Archived from the original on 14 April 2017. Retrieved 28 March 2017.
"Novavax RSV vaccine found safe for pregnant women, fetus". Reuters. 29 September 2016. Archived from the original on 7 October 2016. Retrieved 28 March 2017.
Herper, Matthew. "Gates Foundation Backs New Shot To Prevent Babies From Dying Of Pneumonia". Forbes. Archived from the original on 21 September 2016. Retrieved 28 March 2017.
Sagonowsky, Eric (11 May 2020). "Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine work". FiercePharma. Archived from the original on 16 May 2020. Retrieved 12 May 2020.
Gilgore, Sara (26 February 2020). "Novavax is working to advance a potential coronavirus vaccine. So are competitors". Washington Business Journal. Archived from the original on 16 March 2020. Retrieved 6 March 2020.
Nidhi Parekh (24 July 2020). "Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19". Archived from the original on 22 November 2020. Retrieved 24 July 2020.
"Our portfolio". Coalition for Epidemic Preparedness Innovations. Archived from the original on 21 October 2022. Retrieved 18 July 2023.
Research, Center for Biologics Evaluation and (2 October 2023). "Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) Authorized For Individuals 12 Years of Age and Older". FDA. Archived from the original on 5 May 2023.
"May 16, 2025 Approval Letter - NUVAXOVID". FDA. 16 May 2025. Archived from the original on 17 May 2025. Retrieved 18 May 2025.
"Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate". Novavax Inc. (Press release). Archived from the original on 13 June 2021. Retrieved 19 June 2021.

worldcat.org

search.worldcat.org

Thomas, Katie; Twohey, Megan (16 July 2020). "How a Struggling Company Won $1.6 Billion to Make a Coronavirus Vaccine". The New York Times. ISSN 0362-4331. Retrieved 29 January 2021.
Zimmer, Carl (1 November 2021). "The Novavax vaccine, backed by Operation Warp Speed, has won its first authorization — in Indonesia". The New York Times. ISSN 0362-4331. Retrieved 15 December 2021.

yahoo.com

finance.yahoo.com

Khemlani, Anjalee. "Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals". Yahoo! Finance. Retrieved 7 March 2025.
"Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters". yahoo.com. 9 June 2021.
"Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron". yahoo finance. 23 December 2021.
"World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine". finance.yahoo.com. Retrieved 21 December 2021.